-AstraZeneca - Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Press/Media

Period31 Mar 2020

Media coverage

1

Media coverage

  • Title-AstraZeneca - Brilinta reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial
    Media name/outletENP Newswire
    Country/TerritoryUnited Kingdom
    Date31/03/20
    PersonsRoxana Mehran,
View all 1
View less